With the expiration of Boehringer Ingelheim’s patent on Empagliflozin, several Indian pharmaceutical companies are set to ...
A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared ...
The Indian Pharmaceutical Alliance refutes a study claiming Indian generic drugs have higher adverse events, stating quality ...
India’s Contract Development and Manufacturing Organization (CDMO) market is witnessing a strong growth trajectory driven by ...
Dilip Shanghvi, chairman of India's largest drugmaker Sun Pharma, told an industry gathering last week that his company sells ...
Introduction of a direct-to-patient delivery model for its weight-loss drug in the United States could potentially delay its ...
The Print on MSN1d
Top pharma alliance refutes ‘ill-researched’ US study linking Indian generics to higher adverse eventsIndian Pharmaceutical Alliance says the study relies on FDA Adverse Event Reporting System data, which captures link between ...
Dehradun: An Indian pharmaceutical firm, whose products Singapore's Health Sciences Authority (HSA) allegedly issued images ...
Under the deal, Sun Pharma will buy the outstanding shares ... 66% to Checkpoint’s closing share price last Friday, the Indian pharmaceutical giant said in a statement on Monday.
India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics , a U.S.-based immunotherapy and targeted oncology company, for $355 million.
1don MSN
New Delhi, A trends study conducted by the federal financial intelligence unit of India has expressed "suspicion" that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback